PORTALE DELLA DIDATTICA

Ricerca CERCA
  KEYWORD

28- biomedica

Antimicrobial (drug) resistance and drug discovery

azienda Tesi esterna in azienda    


Parole chiave ANTIBIOTICS, DRUG RESISTANCE, BACTERIA, DRUG DESIG

Riferimenti MARCO AGOSTINO DERIU, JACEK ADAM TUSZYNSKI

Riferimenti esterni Prof. Daniel Charlebois, University of Alberta

Gruppi di ricerca 28- biomedica

Descrizione Drug resistance is a health crisis that is undermining advances in modern medicine and is predicted to kill 10 million people per year globally by 2050. The proposed research will involve testing predictions from molecular dynamics simulations (in collaboration with Dr. Jack Tuszynski’s group) and computational modeling via laboratory experiments. These experiments will involve testing novel compounds, as well as common antibiotics and antifungal drugs, on bacteria (E. coli), budding yeast (S. cerevisiae) strains genetically engineered to carry synthetic drug resistance gene networks, and pathogenic yeasts (C. albicans, C. glabrata, and C. auris). The overall aim of this research program is to develop effective, “evolution proof” drug treatment strategies for patients with drug resistant infections. The Charlebois Lab at the University of Alberta, Edmonton, Canada will host the internship student for a period of 4-6 months as part of this project.

Conoscenze richieste basic bioengineering techniques; cell culture


Scadenza validita proposta 21/12/2020      PROPONI LA TUA CANDIDATURA




© Politecnico di Torino
Corso Duca degli Abruzzi, 24 - 10129 Torino, ITALY
Contatti